Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Supportive Care
•
Immune-related adverse events
•
Neurology
•
Endocrinology
•
General Endocrinology
How do you manage suspected hypophysitis/hypopituitarism as an immune-related adverse event?
What lab tests/imaging do you obtain and how do you initially treat?
Related Questions
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
How would you advise medical oncologists who recommend checkpoint inhibitors for a patient with baseline type 1 diabetes?
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
Are you using olanzapine to treat cancer cachexia after the results of the OlAnCa trial?
What is your experience with in vitro chemosensitivity testing?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
In general, how do you manage patients with early-stage endometrioid endometrial cancer who have concomitant POLE and TP53 mutations?